BBIO vs. OGN, APLS, MDGL, IONS, NUVL, ALPN, PRGO, ALKS, INSM, and BPMC
Should you be buying BridgeBio Pharma stock or one of its competitors? The main competitors of BridgeBio Pharma include Organon & Co. (OGN), Apellis Pharmaceuticals (APLS), Madrigal Pharmaceuticals (MDGL), Ionis Pharmaceuticals (IONS), Nuvalent (NUVL), Alpine Immune Sciences (ALPN), Perrigo (PRGO), Alkermes (ALKS), Insmed (INSM), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical preparations" industry.
Organon & Co. (NYSE:OGN) and BridgeBio Pharma (NASDAQ:BBIO) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, community ranking, institutional ownership, valuation and dividends.
In the previous week, BridgeBio Pharma had 9 more articles in the media than Organon & Co.. MarketBeat recorded 16 mentions for BridgeBio Pharma and 7 mentions for Organon & Co.. BridgeBio Pharma's average media sentiment score of 0.77 beat Organon & Co.'s score of 0.70 indicating that Organon & Co. is being referred to more favorably in the media.
77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 99.8% of BridgeBio Pharma shares are owned by institutional investors. 1.2% of Organon & Co. shares are owned by company insiders. Comparatively, 28.5% of BridgeBio Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Organon & Co. has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500.
Organon & Co. presently has a consensus target price of $22.60, indicating a potential upside of 5.02%. BridgeBio Pharma has a consensus target price of $48.00, indicating a potential upside of 54.64%. Given Organon & Co.'s stronger consensus rating and higher possible upside, analysts plainly believe BridgeBio Pharma is more favorable than Organon & Co..
BridgeBio Pharma received 124 more outperform votes than Organon & Co. when rated by MarketBeat users. Likewise, 67.63% of users gave BridgeBio Pharma an outperform vote while only 33.33% of users gave Organon & Co. an outperform vote.
Organon & Co. has a net margin of 16.50% compared to Organon & Co.'s net margin of -246.24%. Organon & Co.'s return on equity of 0.00% beat BridgeBio Pharma's return on equity.
Organon & Co. has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.
Summary
BridgeBio Pharma beats Organon & Co. on 12 of the 19 factors compared between the two stocks.
Get BridgeBio Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BridgeBio Pharma Competitors List
Related Companies and Tools
